TABLE 6.
Treatment-emergent, drug-related adverse events in patients with CSSTIs treated with linezolid or comparator drugs
| Adverse event(s) | No. (%) of patients treated with:
|
P value | |
|---|---|---|---|
| Linezolid (N = 592) | Vancomycina (N = 588) | ||
| Drug-related events | 131 (22.1) | 121 (20.6) | 0.516 |
| Serious adverse events | 2 (<1) | 8 (1.4) | 0.064 |
| Most common events (≥1% in either group) | |||
| Anemia | 7 (1.2) | 10 (1.7) | 0.476 |
| Diarrhea | 31 (5.2) | 9 (1.5) | 0.0006 |
| Headache | 10 (1.7) | 4 (0.7) | 0.177 |
| Nausea | 24 (4.1) | 8 (1.4) | 0.006 |
| Pruritus | 6 (1.0) | 10 (1.7) | 0.328 |
| Rash | 3 (0.5) | 16 (2.7) | 0.002 |
| Thrombocytopenia | 21 (3.5) | 0 | <0.001 |
| Vomiting | 8 (1.4) | 5 (0.9) | 0.579 |
a
Patients could be switched to nafcillin, oxacillin, dicloxacillin, or flucloxacillin based on culture results.